1-1 of 1
Keywords: Tyrosine kinase inhibitor
Close
Sort by
Journal Articles
Biol Open (2023) 12 (8): bio059994.
Published: 15 August 2023
... reveals that the tumor microenvironment (TME) including host immune cells significantly contribute to the therapeutic responses achieved with oncogene-targeted agents like tyrosine kinase inhibitors (TKIs) and KRAS G12C -targeted agents ( Boumelha et al., 2022 ; Canon et al., 2019 ; Kleczko et al...
Includes: Supplementary data